Achilles Therapeutics Plc - ADR

NASDAQ:ACHL  
2.56
+0.08 (+3.23%)
Earnings Announcements

Achilles Therapeutics Reports First Quarter 2022 Financial Results And Recent Business Highlights

Published: 05/10/2022 11:26 GMT
Achilles Therapeutics Plc - ADR (ACHL) - Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights.
Cash Balance of $237 Million Supports All Planned Operations Into 2h 2024.
Qtrly Net Loss per Share Attributable $0.45.
Q1 Earnings per Share View $-0.51 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.62

More details on our Analysts Page.